Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Neuroblastoma 4Ganglioneuroblastoma 2Sarcoma 1Osteosarcoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Melanoma 1Medulloblastoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1Congenital Abnormalities 1Central Nervous System Neoplasms 1Brain Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 7Busulfan 7Cyclophosphamide 6Whole-Body Irradiation 5Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5fludarabine 4Methotrexate 4fludarabine phosphate 3Tacrolimus 3Radiotherapy 3Melphalan 3Daunorubicin 3Cyclosporine 3Asparaginase 3merphos 2Thioguanine 2Patient Reported Outcome Measures 2Mitoxantrone 2Mesna 2Idarubicin 2Granulocyte Colony-Stimulating Factor 2Gemtuzumab 2Filgrastim 2Bone Marrow Transplantation 2Azacitidine 2Antilymphocyte Serum 2zosuquidar trihydrochloride 1treosulfan 1thymoglobulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Myelodysplastic Syndromes × Colony-Stimulating Factors × Clear all
NCT00046930 2023-07-05

Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia

Eastern Cooperative Oncology Group

Phase 3 Completed
449 enrolled 9 charts
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡